InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $8.200 0.07 (0.86%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$414 Placement 25 Jun 2012 9:47AM $1.600 $8.200 risen by 412.50%
$414 Trading Halt 21 Jun 2012 9:02AM $1.600 $8.200 risen by 412.50%
$414 Clinuvel commences US Phase III trial of SCENESSE 22 May 2012 5:57PM $1.700 $8.200 risen by 382.35%
$414 Appendix 4C - quarterly 30 Apr 2012 8:26AM $1.760 $8.200 risen by 365.91%
$414 Swiss insurers agree to reimburse Clinuvel`s SCENESSE 26 Apr 2012 8:31AM $1.780 $8.200 risen by 360.67%
$414 Clinuvel, FDA agree in principle to Phase III study 15 Mar 2012 10:17AM $1.820 $8.200 risen by 350.55%
$414 Observations from Clinuvel`s programs being presented at AAD 15 Mar 2012 9:18AM $1.820 $8.200 risen by 350.55%
$414 Clinuvel Newsletter - February 2012 29 Feb 2012 6:45PM $1.700 $8.200 risen by 382.35%
$414 Clinuvel files European MAA for SCENESSE (afamelanotide) 6 Feb 2012 6:12PM $2.200 $8.200 risen by 272.73%
$414 Response to ASX price query 13 Jan 2012 8:42AM $2.120 $8.200 risen by 286.79%
$414 Clinuvel - positive results from pivotal Phase III EPP study 20 Dec 2011 8:27AM $1.485 $8.200 risen by 452.19%
$414 Encouraging interim safety results in Phase II OTR study 15 Dec 2011 9:49AM $1.505 $8.200 risen by 444.85%
$414 Clinuvel granted US topical formulation patent 8 Nov 2011 8:23AM $1.480 $8.200 risen by 454.05%
$414 Media release - US Phase II results 3 Nov 2011 7:10PM $1.480 $8.200 risen by 454.05%
$414 Clinuvel announces positive results of Phase II US study 3 Nov 2011 7:06PM $1.480 $8.200 risen by 454.05%
$414 First positive observations from Clinuvel`s vitiligo trial 21 Oct 2011 9:04AM $1.510 $8.200 risen by 443.05%
$414 Appendix 4C - quarterly 14 Oct 2011 5:23PM $1.450 $8.200 risen by 465.52%
$414 Clinuvel completes pre-clinical program for SCENESSE 31 Aug 2011 5:38PM $1.600 $8.200 risen by 412.50%
$414 Appendix 4E - Preliminary Final Report 25 Aug 2011 5:39PM $1.510 $8.200 risen by 443.05%
$414 Appendix 4C - quarterly 27 Jul 2011 5:28PM $1.600 $8.200 risen by 412.50%
$414 Clinuvel records first A$1 million in sales 23 Jun 2011 8:28AM $1.700 $8.200 risen by 382.35%
$414 Clinuvel granted Australian formulation patent 24 May 2011 9:07AM $1.800 $8.200 risen by 355.56%
$414 EMA acknowledges Clinuvel filing afamelanotide in Europe `11 12 May 2011 10:16AM $1.890 $8.200 risen by 333.86%
$414 Clinuvel books European Pre-Submission Meeting for SCENESSE 20 Apr 2011 9:48AM $2.000 $8.200 risen by 310%
$414 Appendix 4C - quarterly 19 Apr 2011 8:53AM $1.850 $8.200 risen by 343.24%

751 - 775 of 880 results

Page 31 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.